WO2005017123A3 - Mptens utilises comme modificateurs de la voie pten et procedes d'utilisation - Google Patents
Mptens utilises comme modificateurs de la voie pten et procedes d'utilisation Download PDFInfo
- Publication number
- WO2005017123A3 WO2005017123A3 PCT/US2004/026492 US2004026492W WO2005017123A3 WO 2005017123 A3 WO2005017123 A3 WO 2005017123A3 US 2004026492 W US2004026492 W US 2004026492W WO 2005017123 A3 WO2005017123 A3 WO 2005017123A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- mptens
- modifiers
- pten
- pten pathway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Selon la présente invention, des gènes MPTEN humains ont été identifiés comme modulateurs de la voie PTEN, et constituent par conséquent des cibles thérapeutiques dans les troubles associés à un fonctionnement défectueux de PTEN. L'invention porte sur des procédés permettant d'identifier des modulateurs de PTEN, selon lesquels on procède à un criblage d'agents qui modulent l'activité de MPTEN.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49504903P | 2003-08-14 | 2003-08-14 | |
US60/495,049 | 2003-08-14 | ||
US52454903P | 2003-11-24 | 2003-11-24 | |
US60/524,549 | 2003-11-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005017123A2 WO2005017123A2 (fr) | 2005-02-24 |
WO2005017123A3 true WO2005017123A3 (fr) | 2006-06-01 |
Family
ID=34198023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/026492 WO2005017123A2 (fr) | 2003-08-14 | 2004-08-12 | Mptens utilises comme modificateurs de la voie pten et procedes d'utilisation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005017123A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012020839A1 (fr) * | 2010-08-12 | 2012-02-16 | 塩野義製薬株式会社 | Composition pharmaceutique destinée à la thérapie du cancer |
KR101540319B1 (ko) * | 2013-10-01 | 2015-07-30 | 한국생명공학연구원 | cyb5R3 유전자 또는 단백질을 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020150954A1 (en) * | 2000-05-30 | 2002-10-17 | Durden Donald L. | Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways |
WO2005002418A2 (fr) * | 2003-06-19 | 2005-01-13 | Exelixis, Inc. | Mpten en tant que modulateurs du passage pten/igf et procedes d'utilisation |
WO2005003297A2 (fr) * | 2003-05-14 | 2005-01-13 | Exelixis, Inc. | Genes mpten utilises en tant que modificateurs de la voie pten/igf et procedes d'utilisation associes |
-
2004
- 2004-08-12 WO PCT/US2004/026492 patent/WO2005017123A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020150954A1 (en) * | 2000-05-30 | 2002-10-17 | Durden Donald L. | Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways |
WO2005003297A2 (fr) * | 2003-05-14 | 2005-01-13 | Exelixis, Inc. | Genes mpten utilises en tant que modificateurs de la voie pten/igf et procedes d'utilisation associes |
WO2005002418A2 (fr) * | 2003-06-19 | 2005-01-13 | Exelixis, Inc. | Mpten en tant que modulateurs du passage pten/igf et procedes d'utilisation |
Non-Patent Citations (3)
Title |
---|
KISHIMOTO H ET AL: "Physiological functions of PTEN in mouse tissues.", CELL STRUCTURE AND FUNCTION., vol. 28, 28 February 2003 (2003-02-28), pages 11 - 21 * |
TORRES J ETAL: "Phosphorylation-regulated cleavage for the tumor suppressor PTEN by Caspase-3.", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 278, 3 June 2003 (2003-06-03), pages 30652 - 30660 * |
VIROLLET ET AL: "EGR-1 transcription factor directly activates PTEN during irradiation induced signalling.", NATURE CELL BIOL., vol. 3, December 2001 (2001-12-01), pages 1124 - 1128 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005017123A2 (fr) | 2005-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007002188A3 (fr) | Genes mptenakt en tant genes modificateurs de la voie pten/akt et methodes d'utilisation | |
WO2005016287A3 (fr) | Prkwnk utilises en tant que modificateurs de la voie rac et methodes d'utilisation associees | |
WO2003051905A3 (fr) | Taojik utilises en tant que modificateurs de la voie beta-catenine et procedes d'utilisation associes | |
WO2005002418A3 (fr) | Mpten en tant que modulateurs du passage pten/igf et procedes d'utilisation | |
WO2005003297A3 (fr) | Genes mpten utilises en tant que modificateurs de la voie pten/igf et procedes d'utilisation associes | |
WO2004024882A3 (fr) | Flj20647 utilise en tant que modificateur de la voie p21 et procedes d'utilisation associes | |
WO2004013309A3 (fr) | Papss comme modificateurs de la voie d'axin et procédés d'utilisation | |
WO2005090992A3 (fr) | Genes mpten modifiant le trajet pten, et procedes d'utilisation | |
WO2006099182A3 (fr) | Mptenakt utilises en tant que modificateurs de la voie pten/akt et procedes d'utilisation associes | |
WO2005017123A3 (fr) | Mptens utilises comme modificateurs de la voie pten et procedes d'utilisation | |
WO2004005483A3 (fr) | Adcy3s modificateurs de la voie p21 et methodes d'utilisation | |
WO2004014301A3 (fr) | Genes psmc utilises comme modificateurs du trajet retiniblastome (rb) et techniques d'utilisation | |
WO2004048538A3 (fr) | Caseine kinases modifiant la voie rac et leurs procedes d'utilisation | |
WO2004015071A3 (fr) | Genes csnk1gs utilises en tant que modificateurs de la voie p21 et procede d'utilisation associe | |
WO2005001026A3 (fr) | Adenosines kinases en tant que modificateurs de la voie pten et leurs procedes d'utilisation | |
WO2004005486A3 (fr) | Genes mp21 utilises comme modificateurs de la voie p21 et leurs procedes d'utilisation | |
WO2004083389A3 (fr) | Genes mbcat utilises comme modificateurs de la voie de la beta-catenine et techniques d'utilisation | |
WO2004048541A3 (fr) | Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants | |
WO2003074725A3 (fr) | Mbcat comme modificateurs du mecanisme d'action de la $g(b)-catenine et procedes d'utilisation correspondants | |
WO2004061123A3 (fr) | Mbcat servant de modificateurs de la voie de beta-catenine et leurs procedes d'utilisation | |
WO2005051310A3 (fr) | Genes ctps utilises en tant que modificateurs de la voie pten et procedes d'utilisation associes | |
WO2003074673A3 (fr) | Lgals tenant lieu de modificateurs de la voie de chk et leurs procedes d'utilisation | |
WO2003074677A3 (fr) | Mchk comme modulateurs du mecanisme d'action de chk et procedes d'utilisation | |
WO2005052134A3 (fr) | Tau-tubuline kinases utilisees comme modificateurs de la voie de la beta-catenine et leurs procedes d'utilisation | |
WO2005052130A3 (fr) | Genes nrbp utilises en tant que modificateurs de la voie rac et procedes d'utilisation associes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |